Insilico Medicine’s Post

Gevorg Grigoryan, PhD, our CTO and co-founder, will be speaking at Genetic Engineering & Biotechnology News' State of AI in Drug Discovery 2024 virtual summit on Wednesday, October 30, at 2:00pm ET. In the panel, “From Computational Platforms to Protein Therapeutics,” Gevorg will explore how #AI-driven platforms are accelerating the design of novel and more effective therapeutics. Moderators Fay Lin, PhD and Kevin Davies, PhD from Genetic Engineering & Biotechnology News will lead the conversation as Gevorg joins Ava Amini from Microsoft and Karen Akinsanya from Schrödinger to discuss AI’s role in transforming drug discovery. Curious to see where AI is taking drug development? https://lnkd.in/eP2Jt3yU #ProgrammingBiology | #GenerativeAI

ICYMI: Our CTO and co-founder, Gevorg Grigoryan, joined GEN’s "State of AI in Drug Discovery 2024" for the panel, “From Computational Platforms to #ProteinTherapeutics.” Moderated by Fay Lin, PhD, Senior Editor at Genetic Engineering & Biotechnology News, they discussed how #AI-driven platforms are accelerating the design of novel and more effective therapeutics. Curious to see where AI is taking drug development? Watch the replay here: https://lnkd.in/gdArARDq #ProgrammingBiology | #GenerativeAI

🔬 Thrilled to Present at SynBioBeta 2024! 🔬 Join Cedric Wu, VP of Innovation Center at GenScript USA Inc., on May 7th from 1:45 PM to 2:30 PM in the Grand Ballroom 220A for our session on "Accelerating Revolution in Biotech and BioPharma: The Power of Precision Mutant Libraries." 🧬 Discover the cutting-edge advancements in high-throughput DNA variant libraries that are reshaping protein engineering, target identification, and the development of gene and cell therapies. We'll explore how precision mutant DNA libraries, validated by deep learning models, are unlocking potential in areas like AAV capsids, enhancing tissue organ tropism, and CAR-T therapy design. 🌐 Whether you are involved in biopharma, bioengineering, or genomics, this session will provide a deep dive into the technologies driving rapid advancements in medical research and therapeutic development. Join us! https://lnkd.in/eWR-27hi #SynBioBeta2024 #Biopharma #GenScript #PrecisionHealth

Interesting article from genengnews.com!

🦤 Psssst…this week’s edition is filled with intrigue: from high-level exits to secret funding deals. It’s all hush-hush for now, but we’re here to lift the lid👇 👣 BenevolentAI CEO steps down as founders make a comeback (Phil Taylor) 🤫 Secretive Treeline Biosciences discloses $421M financing in filing (Nick Paul Taylor) 👻 Another Roche MAGE-A4 trial withdrawn (Liam Casey) 💰Ontario invests $146M in hopes of becoming life sciences hub (Dr. Sushama Chaphalkar) 🔬Researchers uncover the potential of JAK inhibitors to treat life-threatening skin disease (Kyle LaHucik, Andrew Dunn) Tune into… 🎧 Tips for Effective Communication in Biotech with Carolyn Scofield, MPS 🎧 Replacing Cells, Restoring Sight with Brian Culley 🎧 The future of gene therapy with Michael Parini Apply to… 📎 Upstream Bioprocess Lead, NanoSyrinx 📎 Senior Scientist in Bio-Physics, Domainex 📎 Scientist II/III Process Development, Oxford Biomedica Stay up to date with all the latest biotech news and sign up for the weekly Biotech Dodo Newsletter. Issue #19 out now: https://lnkd.in/ewqdH36A #biotechdodo #biotech #pharma #digitalhealth #healthtech

Our very first customer success case study is now available! 🤩 “Limiting dilution involves subjective judgment, which can be difficult to document comprehensively,” remarked Dr. Suzanne Snellenberg. Not with UP.SIGHT. 💡 Using CYTENA's flagship single-cell dispenser and plate imager, Cellistic has achieved high iPSC recovery rates (>50%), reduced errors and labor-intensive work in cell sorting, improved data traceability, streamlined the cloning process, and thus saved time and resources for future lab research. The impact UP.SIGHT has made in Cellistic's lab:  ✨ 90% gene editing efficiency ✨ >50% recovery from single iPSCs Read the full case study to see how you can boost gene editing efficiency and monoclonality in iPSCs, just like Cellistic did! 📖👇 https://lnkd.in/dWzKjvu6 📣 Stay tuned for more customer success stories to come... https://lnkd.in/dzpGCktN #CellTherapy #iPSC #GeneEditing #Biotech #Innovation #SuccessCaseStudy #Automation #UPSIGHT #SingleCellDispenser #PlateImager

Good morning, intrepid readers. As usual, I come bearing biotech news…🦤 This week, Harvard’s whiz-kids unveil a new RNA synthesis method, Flagship Pioneering secures a cosmic $3.6bn raise, while Interius embarks on a Phase I trial in Australia for CAR-T therapy, and a new microbiome gene editing technique comes under the microscope. Finally, investors are back on deck after the funding slump – but is all as it seems? This week’s biotech roundup includes…👇 🧬 Harvard scientist’s enzymatic RNA synthesis tech (Genetic Engineering & Biotechnology News) 💉 Moderna’s Biotech investor raises $3.6bn for new ventures (Oliver Barnes) 🇦🇺 Interius starts Phase I trial of in vivo CAR-T therapy (Tristan Cesar Mañalac) 🐭 Eligo Bioscience achieves first in vivo microbiome base editing (Karen O'Hanlon Cohrt, PhD) 💸 Funding for biotech startups had its best quarter in two years (Kyle LaHucik Tune into… 🎧 Josh Mandel-Brehm - CEO, CAMP4 Therapeutics (First in Human by Vial and Amy Del Medico) 🎧 Engineering Therapeutic Antibodies (Two Scientists Walk Into a Bar by @Maria Wilson) with Yan Wu, and Paul Carter from Genentech Apply to… 📎 Biostatistician, Medpace 📎 Trainee Patent Attorney, Carpmaels & Ransford Boldly explore the latest biotech news with Biotech Dodo’s weekly round-up. Issue #05 out now: https://lnkd.in/eWP9-Awu #biotechdodo #biotech #pharma #digitalhealth #healthtech

Envisagenics' Co-Founder and CTO, Martin Akerman, PhD, recently presented at RNA USA, hosted by SAE Media Group . He introduced SpliceCore, the AI-driven platform developed to uncover novel therapeutic targets for neurodegenerative diseases like ALS. By leveraging the intricate process of alternative splicing, Martin Akerman highlighted how SpliceCore uses AI/ML to develop splicing-modulatory drugs and its proven ability to identify novel antisense drug targets for neurodegeneration. We’re excited to have shared our innovative technology at RNA USA and to continue pushing the boundaries of RNA-based drug discovery. #RNA #AlternativeSplicing #AIinHealthcare #ALS #Neurodegeneration #Biotech #Envisagenics #RNAUSA #AI #ML

NEW: UK biotech Oxford Nanopore has filed its promised lawsuit against China's BGI over the misuse of confidential information. Both companies develop gene sequencing tech and the case centres around claims that BGI used trade secrets from Oxford Nanopore to develop its technology.

🚀 Scientists from Google DeepMind unveil #AlphaProteo, a groundbreaking #AI system for designing novel, high-strength protein binders. This innovation could accelerate biological and health research, aiding drug discovery, biosensor development, and more. 🎯 AlphaProteo demonstrates unprecedented capabilities, including the first-ever AI-designed protein binder for VEGF-A, a protein linked to cancer and diabetes complications. The system shows potential to revolutionize our understanding of biological processes. 💡 In tests with seven target proteins, AlphaProteo outperforms existing methods, achieving higher experimental success rates and binding affinities 3 to 300 times better. This leap in efficiency could significantly speed up research and development in life sciences. Quick Read: https://lnkd.in/gaguUgdz Video: https://lnkd.in/gYVmSGKU #Bioinformatics #ComputationalBiology #DrugDiscovery #ArtificialIntelligence #BiotechBreakthrough #AIinBiology #ScienceNews #biotechnology